0001179110-17-012520.txt : 20170920 0001179110-17-012520.hdr.sgml : 20170920 20170920173944 ACCESSION NUMBER: 0001179110-17-012520 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170918 FILED AS OF DATE: 20170920 DATE AS OF CHANGE: 20170920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haviland Kate CENTRAL INDEX KEY: 0001663022 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 171094702 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORPORATION STREET 2: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2017-09-18 0 0001597264 Blueprint Medicines Corp BPMC 0001663022 Haviland Kate C/O BLUEPRINT MEDICINES CORPORATION 38 SIDNEY STREET, SUITE 200 CAMBRIDGE MA 02139 0 1 0 0 Chief Business Officer Common Stock 2017-09-18 4 M 0 6356 16.28 A 6356 D Common Stock 2017-09-18 4 S 0 6356 60.03 D 0 D Stock Option (Right to Buy) 16.28 2017-09-18 4 M 0 6356 0 D 2026-02-01 Common Stock 6356 107308 D The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.20 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. /s/ Christopher Frankenfield, Attorney-in-Fact 2017-09-18